List of Intermezzo drug patents
Intermezzo is owned by Purdue Pharma.
Intermezzo contains Zolpidem Tartrate.
Intermezzo has a total of 4 drug patents out of which 0 drug patents have expired.
Intermezzo was authorised for market use on 23 November, 2011.
Intermezzo is available in tablet;sublingual dosage forms.
Intermezzo can be used as method of treating middle-of-the-night insomnia, method for treating insomnia.
The generics of Intermezzo are possible to be released after 20 August, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7682628 | PURDUE PHARMA | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Feb, 2025
(2 years from now) | |
| US8252809 | PURDUE PHARMA | Compositions for treating insomnia |
Feb, 2025
(2 years from now) | |
| US7658945 | PURDUE PHARMA | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Apr, 2027
(4 years from now) | |
| US8242131 | PURDUE PHARMA | Methods of treating middle-of-the-night insomnia |
Aug, 2029
(6 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 23 November, 2011
Treatment: Method for treating insomnia; Method of treating middle-of-the-night insomnia
Dosage: TABLET;SUBLINGUAL
INTERMEZZO family patents
31
United States
8
Korea, Republic of
3
Canada
3
Japan
2
Brazil
2
South Africa
2
Australia
2
New Zealand
2
Mexico
2
China
2
European Union
1
Hong Kong
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic